Gastrointestinal Cancer
From the Journals
Global incidence, deaths from CRC doubled over past 3 decades
Those born in the second half of the 20th century are increasingly exposed to potentially modifiable risk factors, such as an unhealthy diet,...
From the Journals
Two rounds of FIT vs. single colonoscopy as a one-time CRC screening
Two FITs spaced 2 years apart could change the approach to colorectal cancer screening if it shows a mortality benefit, according to a preliminary...
Guidelines
New Barrett’s esophagus guideline reduces reliance on endoscopy
A new guideline for Barrett’s esophagus endorses a less invasive approach to screening.
From the Journals
Live-donor liver transplants for patients with CRC liver mets
"For the first time, we have been able to demonstrate [outside of Norway] that liver transplantation for patients with unresectable liver...
From the Journals
Locoregional therapy lowers waitlist dropout in HCC
Bridging strategies with locoregional therapy are recommended for liver transplant candidates who have to wait 6 months or longer for transplant...
From the Journals
Obesity increasing the risk for cancer: It’s complicated
For some cancers it was “very clear that obesity increased the risk ... but for some other cancer types, we either don’t have enough data yet or...
From the Journals
Cancer of the appendix on the rise in younger patients with appendicitis
“There is a push to treat acute appendicitis with only antibiotics ... an appendiceal cancer can be missed if the appendix is not removed.”
Latest News
Cardiac monitoring suggested for advanced RCC patients with high troponin T levels after combo treatment
Troponin T levels may help determine who is at most risk of cardiovascular events after receiving immune checkpoint and VEGF inhibitors.
From the Journals
Artificial sweeteners: A modifiable cancer risk?
“Our findings do not support the use of artificial sweeteners as safe alternatives for sugar in foods or beverages,” said the researchers. An...
From the Journals
Immunotherapy treatment shows promise for resectable liver cancer
Positive phase 2 results pave the way for phase 3 studies.
From the Journals
Few new cancer drugs replace current standards of care
Newer drugs could benefit patients but could increase the cost of care.